ImmunoMet Therapeutics
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd, Houston, Texas, 7702...Phone Number
(346) 772-0318Website
www.immunomet.comRevenue
$10.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About ImmunoMet Therapeutics
ImmunoMet is a clinical stage biotechnology company targeting metabolism for the treatment of fibrotic diseases and cancer. ImmunoMet's lead molecule, IM156, is a PC1 inhibitor and is the first potent PC1 inhibitor to complete Phase 1 with good tolerability. In addition to IM156, ImmunoMet owns a large library of biguanides with the potential for development, internally or with partners, for multiple indications. The company was founded in 2015, is headquartered in JLABS @ TMC in Houston and has raised $31M to date.Explore more
ImmunoMet Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmunoMet Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ImmunoMet Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at ImmunoMet Therapeutics
Funding: Get notified immidiatlly once ImmunoMet Therapeutics has new funding data
Click to see if ImmunoMet Therapeutics had a recent Job posting/layoffs
Check if ImmunoMet Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ImmunoMet Therapeutics recently announced quarterly report
ImmunoMet Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ImmunoMet Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined ImmunoMet Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to ImmunoMet Therapeutics
Compare insights from companies similar to ImmunoMet Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
2016
AH
Angela HeeHead Executive Director, Clinical Operations & Project Management
Company Profile Activity
Activity Insights
ImmunoMet Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ImmunoMet Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ImmunoMet Therapeutics.
ImmunoMet Therapeutics financials insights
Gather financial insights about ImmunoMet Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$5.2M
2017
Series B
$5M
2026
Private Equity
$843K
ImmunoMet Therapeutics Tech Stack
A closer look at the technologies used by ImmunoMet Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Executive Move
Left Company
Executive Move
New Hire
Executive Move
Allan Shaw has joined the company to serve as Chief Financial Officer. In this role, Shaw will oversee financial functions for the company. Previously, Shaw served as CFO & Treasurer at Syndax Pharmaceuticals.
Executive Moves, New Hire, Accounting
New Hire
Executive Move
Executive Moves, New Hire
ImmunoMet Therapeutics News & Media
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer.Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer - Opera News
ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics today announced that Dr. Revati Shreeniwas has joined the company as Chief Medical Officer.ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis
HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., today announced that the U.S. FDA has granted Fast Track designation for IM156 in idiopathic pulmonary fibrosis (IPF).
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmunoMet Therapeutics
Sign Up For FreeTo access detailed company insights
ImmunoMet is a clinical stage biotechnology company targeting metabolism for the treatment of fibrotic diseases and cancer. ImmunoMet's lead molecule, IM156, is a PC1 inhibitor and is the first potent PC1 inhibitor to complete Phase 1 with good tolerability. In addition to IM156, ImmunoMet owns a large library of biguanides with the potential for d... Read More
